• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Amazon Is Trading Higher By 12%: Here Are 23 Stocks Moving Premarket

    7/29/22 6:50:26 AM ET
    $AKBA
    $AMZN
    $AVTR
    $AVYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Catalog/Specialty Distribution
    Consumer Discretionary
    Get the next $AKBA alert in real time by email

    Gainers

    • Getty Images Holdings, Inc. (NYSE:GETY) rose 104.5% to $21.47 in pre-market trading.
    • ThermoGenesis Holdings, Inc. (NASDAQ:THMO) rose 34.3% to $0.2850 in pre-market trading after gaining over 6% on Thursday.
    • ECB Bancorp, Inc. (NASDAQ:ECBK) rose 34.1% to $18.90 in pre-market trading after jumping more than 40% on Thursday.
    • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) rose 23.3% to $0.6455 in pre-market trading. The U.S. Food and Drug Administration (FDA) recently declined to issue an Emergency Use Authorization (EUA) for NRx Pharmaceuticals’ lead drug ZYESAMI (aviptadil) for subgroup of patients with critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir.
    • Senti Biosciences, Inc. (NASDAQ:SNTI) rose 19.4% to $2.22 in pre-market trading after declining 5% on Thursday.
    • CHW Acquisition Corporation (NASDAQ:CHWA) rose 16.8% to $10.80 in pre-market trading. CHW Acquisition’s stockholders approved proposed merger transaction with Wag Labs, Inc.
    • Amazon.com, Inc. (NASDAQ:AMZN) rose 12% to $136.90 in pre-market trading after the company reported better-than-expected results for its second quarter. The company said it expects-third quarter net sales to be in a range of $125 billion to $130 billion, up 13% to 17% year-over-year.
    • MICT, Inc. (NASDAQ:MICT) rose 10.5% to $0.6749 in pre-market trading after declining 9% on Thursday.
    • RCM Technologies, Inc. (NASDAQ:RCMT) rose 9.9% to $18.40 in pre-market trading after declining around 9% on Thursday.
    • Reviva Pharmaceuticals Holdings, Inc.. (NASDAQ:RVPH) rose 8.9% to $0.9178 in pre-market trading.
    • Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ:BHAT) rose 8.7% to $2.75 in pre-market trading after dropping 5% on Thursday.
    • Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) rose 6.3% to $2.55 in pre-market trading. Lexicon Pharmaceuticals shares dropped around 27% on Thursday after the company announced pricing of an $85 million public offering and concurrent private placement.
    • CarLotz, Inc. (NASDAQ:LOTZ) shares rose 5.7% to $0.46 in pre-market trading. CarLotz is expected to release its Q2 results on August 8, 2022.
    • Akebia Therapeutics, Inc. (NASDAQ:AKBA) rose 5.4% to $0.42 in pre-market trading. Akebia Therapeutics is expected to release its Q2 financial results on Thursday, August 4, 2022.
    • Apple Inc. (NASDAQ:APPL) rose 2.3% to $161.03 in pre-market trading as the company reported better-than-expected results for its fiscal year third-quarter, helped by strong iPhone and iPad sales.

    Don’t forget to check out our premarket coverage here .

    Losers

    • Roku, Inc. (NASDAQ:ROKU) shares fell 24.3% to $64.45 in pre-market trading after the company reported weaker-than-expected financial results for its second quarter and withdrew its full-year revenue growth guidance. Roku said it expects third-quarter revenue to increase about 3% year-over-year to $700 million.
    • DexCom, Inc. (NASDAQ:DXCM) fell 15.5% to $73.40 in pre-market trading after the company reported worse-than-expected Q2 EPS and sales results.
    • Avaya Holdings Corp. (NASDAQ:AVYA) fell 13.8% to $1.80 in pre-market trading after the company cut Q3 revenue guidance. Avaya also named Alan Masarek as CEO.
    • VolitionRx Limited (NYSE:VNRX) fell 12.3% to $2.00 in pre-market trading after the company announced a proposed underwritten public offering of common stock.
    • Missfresh Limited (NASDAQ:MF) shares fell 10.6% to $0.1210 in pre-market trading after the company adopted significant business strategy adjustments. The company received RMB200 million equity investment pursuant to investment agreement and highlighted temporary shutdown of on-demand distributed mini warehouse.
    • Avantor, Inc. (NYSE:AVTR) shares fell 10.2% to $29.00 in pre-market trading after the company reported worse-than-expected Q2 EPS and sales results.
    • Intel Corporation (NASDAQ:INTC) fell 9.8% to $35.84 in pre-market trading after the company reported worse-than-expected Q2 EPS and sales results. The company also issued Q3 and FY22 EPS and sales guidance below analyst estimates.
    • ObsEva SA (NASDAQ:OBSV) fell 7.3% to $0.2801 in pre-market trading as the company reported the resignation of Jean-Pierre Gotteland, Chief Scientific Officer and Head of Research & Development, effective September 30, 2022.
    Get the next $AKBA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKBA
    $AMZN
    $AVTR
    $AVYA

    CompanyDatePrice TargetRatingAnalyst
    Amazon.com Inc.
    $AMZN
    2/6/2026$300.00 → $280.00Buy
    Monness Crespi & Hardt
    Amazon.com Inc.
    $AMZN
    2/6/2026$175.00Buy → Neutral
    DA Davidson
    Roku Inc.
    $ROKU
    2/6/2026$105.00Perform → Outperform
    Oppenheimer
    Amazon.com Inc.
    $AMZN
    2/2/2026$300.00 → $315.00Mkt Outperform
    Citizens JMP
    Amazon.com Inc.
    $AMZN
    1/28/2026$305.00 → $315.00Outperform
    Oppenheimer
    Amazon.com Inc.
    $AMZN
    1/28/2026$303.00 → $308.00Overweight
    KeyBanc Capital Markets
    Amazon.com Inc.
    $AMZN
    1/27/2026$295.00 → $300.00Buy
    Stifel
    Amazon.com Inc.
    $AMZN
    1/27/2026$303.00 → $286.00Buy
    BofA Securities
    More analyst ratings

    $AKBA
    $AMZN
    $AVTR
    $AVYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Monness Crespi & Hardt reiterated coverage on Amazon with a new price target

    Monness Crespi & Hardt reiterated coverage of Amazon with a rating of Buy and set a new price target of $280.00 from $300.00 previously

    2/6/26 8:23:18 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amazon downgraded by DA Davidson with a new price target

    DA Davidson downgraded Amazon from Buy to Neutral and set a new price target of $175.00

    2/6/26 8:06:19 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Roku upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Roku from Perform to Outperform and set a new price target of $105.00

    2/6/26 8:05:48 AM ET
    $ROKU
    Cable & Other Pay Television Services
    Telecommunications

    $AKBA
    $AMZN
    $AVTR
    $AVYA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Summe Gregory L bought $940,000 worth of shares (100,000 units at $9.40) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    2/12/26 5:24:47 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Sullivan Maura Ellen bought $40,700 worth of shares (2,200 units at $18.50) (SEC Form 4)

    4 - ECB Bancorp, Inc. /MD/ (0001914605) (Issuer)

    2/9/26 4:30:02 PM ET
    $ECBK
    Banks
    Finance

    Director Invus Global Management, Llc was granted 22,400,000 shares, bought $2,000,001 worth of shares (1,538,462 units at $1.30) and was granted 367,145 units of Series B Convertible Preferred Stock (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/4/26 4:25:05 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKBA
    $AMZN
    $AVTR
    $AVYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Avicenna Life Sci Master Fund Lp claimed ownership of 1,538,462 shares (SEC Form 3)

    3 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/12/26 9:29:24 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman BOD Wood Anthony J. converted options into 50,000 shares and sold $4,539,699 worth of shares (50,000 units at $90.79) (SEC Form 4)

    4 - ROKU, INC (0001428439) (Issuer)

    2/12/26 6:20:44 PM ET
    $ROKU
    Cable & Other Pay Television Services
    Telecommunications

    Director Summe Gregory L bought $940,000 worth of shares (100,000 units at $9.40) (SEC Form 4)

    4 - Avantor, Inc. (0001722482) (Issuer)

    2/12/26 5:24:47 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKBA
    $AMZN
    $AVTR
    $AVYA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Roku Releases Fourth Quarter and Full Year 2025 Financial Results

    Today, Roku, Inc. (NASDAQ:ROKU) released fourth quarter and full year 2025 results. Visit the Roku investor relations website to view the fourth quarter and full year 2025 letter to shareholders. The company will host a live webcast of its conference call to discuss the results today at 2:00 PM Pacific Time. Participants may access the live webcast in listen-only mode on the Roku investor relations website. An archived webcast of the conference call will also be available following the call. About Roku Roku pioneered streaming on TV. We connect users to the content they love, enable content publishers to build and monetize large audiences, and provide advertisers with unique capabilit

    2/12/26 4:05:00 PM ET
    $ROKU
    Cable & Other Pay Television Services
    Telecommunications

    Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights: Revenue grew 13% year-over-year to $1.260 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 18% on a reported basis and 15% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $323.0 million or 25.6% of revenue, an increase of 860 basis points compared to the fourth quarter of 2024. Non-GAAP operating income* of $331.5 million or 26.3% of reported revenue, an increase of 750 basis points compared to the fourth

    2/12/26 4:03:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Getty Images and NASCAR Renew Multi-Year Agreement

    A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Getty Images (NYSE:GETY), a preeminent global visual content creator and marketplace, today announced the renewal of its long-standing partnership with NASCAR, extending its role as NASCAR's Official Photography Partner, a designation it has held since 2006. The agreement sees Getty Images' team of specialized motorsport photographers deliver high-quality imagery from all races and events in the NASCAR series, including NASCAR Cup Series™, NASCAR O'Reilly Auto Parts Series™, and NASCAR CRAFTSMAN Truck Series™. With exclusive, behind-the-scenes access, Getty

    2/12/26 8:00:00 AM ET
    $GETY
    Real Estate

    $AKBA
    $AMZN
    $AVTR
    $AVYA
    SEC Filings

    View All

    SEC Form 10-K filed by DexCom Inc.

    10-K - DEXCOM INC (0001093557) (Filer)

    2/12/26 5:20:56 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Roku Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ROKU, INC (0001428439) (Filer)

    2/12/26 4:09:00 PM ET
    $ROKU
    Cable & Other Pay Television Services
    Telecommunications

    DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DEXCOM INC (0001093557) (Filer)

    2/12/26 4:03:42 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $AKBA
    $AMZN
    $AVTR
    $AVYA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 11, 2025 - FDA Roundup: March 11, 2025

    For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

    3/13/25 3:14:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    3/28/24 10:46:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    November 14, 2023 - FDA Roundup: November 14, 2023

    For Immediate Release: November 14, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA updated the advisory for the Investigation of Elevated Lead Levels in Cinnamon Applesauce Pouches to include an expanded recall from WanaBana LLC to include Weis and Schnucks-brand cinnamon applesauce pouches. As of November 13, 2023, there

    11/14/23 3:26:18 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AKBA
    $AMZN
    $AVTR
    $AVYA
    Leadership Updates

    Live Leadership Updates

    View All

    Circana Appoints Highly Regarded Business Leaders to Board of Directors

    Chicago, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Circana LLC, a leading global provider of data, insights, and advisory services, today announced the appointment of three new members to its Board of Directors: Brian Cornell, Executive Chair of Target Corp.; Lauren Cooks Levitan, Co-Founder and Co-CEO of ROOT and Lead Independent Director at e.l.f. Beauty, Inc.; and Rohit Prasad, former Senior Vice President and Head Scientist of Artificial General Intelligence at Amazon.com, Inc. "These appointments strengthen the Board's ability to guide Circana's strategy and accelerate the value we deliver to our global clients," said Stuart Aitken, President and CEO of Circana. "We are focused on advancing

    2/11/26 8:00:00 AM ET
    $AMZN
    $TGT
    Catalog/Specialty Distribution
    Consumer Discretionary
    Department/Specialty Retail Stores

    Volition Announces the Appointment of New Distributor for Nu.Q® Discover

    HENDERSON, Nev., Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented: "We are delighted to be working with MBL, a leading provider of clinical research tools in Japan, with a particular focus and track record in autoimmune diseases. "Through our Nu.Q® Discover pillar, we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug developme

    2/10/26 8:07:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Hasbro Announces Additions to Board of Directors

    Doug Bowser and Carla Vernón to join as newest Board members Today, Hasbro, Inc. (NASDAQ:HAS), a leading games, IP and toy company, announced that Doug Bowser, retired President and Chief Operating Officer of Nintendo of America Inc., and Carla Vernón, Chief Executive Officer of The Honest Company, Inc. have been appointed to Hasbro's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120899535/en/ "We are delighted to have Doug and Carla join our seasoned and dynamic Board of Directors," said Rich Stoddart, Chair of Hasbro's Board of Directors. "Doug and Carla bring extensive leadership experience across co

    1/20/26 8:30:00 AM ET
    $AMZN
    $GIS
    $HAS
    Catalog/Specialty Distribution
    Consumer Discretionary
    Packaged Foods
    Consumer Staples

    $AKBA
    $AMZN
    $AVTR
    $AVYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

    SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    12/9/24 9:33:20 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Senti Biosciences Inc.

    SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)

    12/4/24 7:08:03 PM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Getty Images Holdings Inc.

    SC 13D/A - Getty Images Holdings, Inc. (0001898496) (Subject)

    11/22/24 5:10:10 PM ET
    $GETY
    Real Estate

    $AKBA
    $AMZN
    $AVTR
    $AVYA
    Financials

    Live finance-specific insights

    View All

    Roku Releases Fourth Quarter and Full Year 2025 Financial Results

    Today, Roku, Inc. (NASDAQ:ROKU) released fourth quarter and full year 2025 results. Visit the Roku investor relations website to view the fourth quarter and full year 2025 letter to shareholders. The company will host a live webcast of its conference call to discuss the results today at 2:00 PM Pacific Time. Participants may access the live webcast in listen-only mode on the Roku investor relations website. An archived webcast of the conference call will also be available following the call. About Roku Roku pioneered streaming on TV. We connect users to the content they love, enable content publishers to build and monetize large audiences, and provide advertisers with unique capabilit

    2/12/26 4:05:00 PM ET
    $ROKU
    Cable & Other Pay Television Services
    Telecommunications

    Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights: Revenue grew 13% year-over-year to $1.260 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 18% on a reported basis and 15% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $323.0 million or 25.6% of revenue, an increase of 860 basis points compared to the fourth quarter of 2024. Non-GAAP operating income* of $331.5 million or 26.3% of reported revenue, an increase of 750 basis points compared to the fourth

    2/12/26 4:03:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

    Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202 into R/R AML pivotal study and evaluating indication expansion to include newly diagnosed AML and pediatric AML; Preparing for FDA discussions in the first half of 2026 SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may enable an expedited development and review process SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) --  Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generatio

    2/11/26 8:35:00 AM ET
    $SNTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care